Britain’s SkyePharma Plc said its asthma therapy Flutiform got marketing approval from European regulators, sending its shares up 28 percent. The European Commission’s decision comes more than two months after the European Medicines Agency recommended the drug for approval. “We look forward to launches across Europe in the second half of this year,” SkyePharma Chief Executive Peter Grant said. Flutiform is a combination of two commonly prescribed drugs to treat asthma, the corticosteroid fluticasone propionate and the beta-agonist formoterol fumarate, in a metered dose inhaler.
